Accès gratuit
Numéro
Med Sci (Paris)
Volume 27, Numéro 5, Mai 2011
Page(s) 501 - 507
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2011275015
Publié en ligne 25 mai 2011
  1. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989 ; 264 : 4743-4746. [PubMed] [Google Scholar]
  2. Gandrille S, Saposnik B, Aiach M. Le récepteur endothélial à la protéine C (EPCR) : un récepteur à l’interface entre coagulation et système inflammatoire. Hématologie 2001 ; 7 : 418-28. [Google Scholar]
  3. Esmon CT, Fukudome K. Cellular regulation of the protein C pathway. Semin Cell Biol 1995 ; 6 : 259-268. [CrossRef] [PubMed] [Google Scholar]
  4. Dahlback B. Protein S and C4b-binding protein : components involved in the regulation of the protein C anticoagulant system. Thromb Haemost 1991 ; 66 : 49-61. [PubMed] [Google Scholar]
  5. Aiach M, Alhenc-Gelas M, Borgel D, et al. Mutations des protéines de la coagulation et thromboses. Med Sci (Paris) 2006 ; 22 : 985-989. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  6. Rezaie AR. Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C. J Biol Chem 2001 ; 276 : 15567-15570. [CrossRef] [PubMed] [Google Scholar]
  7. Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units : results of the SOAP study. Crit Care Med 2006 ; 34 : 344-353. [CrossRef] [PubMed] [Google Scholar]
  8. Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal 2001 ; 13 : 85-94. [CrossRef] [PubMed] [Google Scholar]
  9. Levi M, de Jonge E, van der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med 2001 ; 29 : S90-S94. [CrossRef] [PubMed] [Google Scholar]
  10. Gando S. Microvascular thrombosis and multiple organ dysfunction syndrome. Crit Care Med 2010 ; 38 : S35-S42. [CrossRef] [PubMed] [Google Scholar]
  11. Levi M, van der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med 2005 ; 15 : 254-259. [CrossRef] [PubMed] [Google Scholar]
  12. van der Poll T, Levi M, Hack CE, et al. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994 ; 179 : 1253-1259. [CrossRef] [PubMed] [Google Scholar]
  13. Jansen PM, Boermeester MA, Fischer E, et al. Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degranulation, and the release of secretory-type phospholipase A2 in sepsis : studies in nonhuman primates after interleukin-1 alpha administration and during lethal bacteremia. Blood 1995 ; 86 : 1027-1034 [PubMed] [Google Scholar]
  14. Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest 1991 ; 88 : 1346-1353. [CrossRef] [PubMed] [Google Scholar]
  15. Esmon CT. Inflammation and thrombosis. J Thromb Haemost 2003 ; 1 : 1343-1348. [CrossRef] [PubMed] [Google Scholar]
  16. McLaughlin JN, Shen L, Holinstat M, et al. Functional selectivity of G protein signaling by agonist peptides and thrombin for the protease-activated receptor-1. J Biol Chem 2005 ; 280 : 25048-25059. [CrossRef] [PubMed] [Google Scholar]
  17. Joyce DE, Nelson DR, Grinnell BW. Leukocyte and endothelial cell interactions in sepsis : relevance of the protein C pathway. Crit Care Med 2004 ; 32 : S280-S286. [CrossRef] [PubMed] [Google Scholar]
  18. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005 ; 105 : 3178-3184. [CrossRef] [PubMed] [Google Scholar]
  19. Sturn DH, Kaneider NC, Feistritzer C, et al. Expression and function of the endothelial protein C receptor in human neutrophils. Blood 2003 ; 102 : 1499-1505. [CrossRef] [PubMed] [Google Scholar]
  20. Elphick GF, Sarangi PP, Hyun YM, et al. Recombinant human activated protein C inhibits integrin-mediated neutrophil migration. Blood 2009 ; 113 : 4078-4085. [CrossRef] [PubMed] [Google Scholar]
  21. Riewald M, Petrovan RJ, Donner A, et al. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002 ; 296 : 1880-1882. [CrossRef] [PubMed] [Google Scholar]
  22. Cao C, Gao Y, Li Y, et al. The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b. J Clin Invest 2010 ; 120 : 1971-1980. [CrossRef] [PubMed] [Google Scholar]
  23. Mahidhara R, Billiar TR. Apoptosis in sepsis. Crit Care Med 2000 ; 28 : N105-N113. [CrossRef] [PubMed] [Google Scholar]
  24. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003 ; 101 : 3765-3777. [CrossRef] [PubMed] [Google Scholar]
  25. Cheng T, Liu D, Griffin JH, et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003 ; 9 : 338-342. [CrossRef] [PubMed] [Google Scholar]
  26. Stephenson DA, Toltl LJ, Beaudin S, Liaw PC. Modulation of monocyte function by activated protein C, a natural anticoagulant. J Immunol 2006 ; 177 : 2115-2122. [PubMed] [Google Scholar]
  27. Conway EM, Van de Wouwer M, Pollefeyt S, et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med 2002 ; 196 : 565-577. [CrossRef] [PubMed] [Google Scholar]
  28. Anderson HA, Maylock CA, Williams JA, et al. Serum-derived protein S binds to phosphatidylserine and stimulates the phagocytosis of apoptotic cells. Nat Immunol 2003 ; 4 : 87-91. [CrossRef] [PubMed] [Google Scholar]
  29. Xu J, Zhang X, Pelayo R, et al. Extracellular histones are major mediators of death in sepsis. Nat Med 2009 ; 15 : 1318-1321. [CrossRef] [PubMed] [Google Scholar]
  30. Viatte L Dr Jekyll et Mr Histone : protéger ou tuer, la dualité des histones. Med Sci (Paris) 2010 ; 26 : 144. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  31. Shorr AF, Bernard GR, Dhainaut JF, et al. C Protein concentrations in severe sepsis : an early directional change in plasma levels predicts outcome. Crit Care 2006 ; 10 : R92. [CrossRef] [PubMed] [Google Scholar]
  32. Taylor FB, Jr., Chang A, Esmon CT, et al. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987 ; 79 : 918-925. [CrossRef] [PubMed] [Google Scholar]
  33. Kerschen EJ, Fernandez JA, Cooley BC, et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med 2007 ; 204 : 2439-2448. [CrossRef] [PubMed] [Google Scholar]
  34. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001 ; 344 : 699-709. [CrossRef] [PubMed] [Google Scholar]
  35. Ely EW, Laterre PF, Angus DC, et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003 ; 31 : 12-19. [CrossRef] [PubMed] [Google Scholar]
  36. Vincent JL, Bernard GR, Beale R, et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE : further evidence for survival and safety and implications for early treatment. Crit Care Med 2005 ; 33 : 2266-2277. [CrossRef] [PubMed] [Google Scholar]
  37. Payen D, Sundin DP, Nelson DR, Williams MD. Analysis of efficacy and safety of drotrecogin alfa (activated) in surgical patients, using an international integrated database. Surgery 2007 ; 142 : 426-427. [CrossRef] [Google Scholar]
  38. Thompson BT, Ranieri VM, Finfer S, et al. Statistical analysis plan of PROWESS SHOCK study. Intensive Care Med 2010 ; 36 : 1972-1973. [CrossRef] [PubMed] [Google Scholar]
  39. Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005 ; 353 : 1332-1341. [CrossRef] [PubMed] [Google Scholar]
  40. Carlet J. Prescribing indications based on successful clinical trials in sepsis : a difficult exercise. Crit Care Med 2006 ; 34 : 525-529. [CrossRef] [PubMed] [Google Scholar]
  41. Vieillard-Baron A, Caille V, Charron C, et al. Reversal of refractory septic shock with drotrecogin alpha (activated). Intensive Care Med 2009 ; 35 : 1204-1209. [CrossRef] [PubMed] [Google Scholar]
  42. Dumont B, Faille D, Ajzenberg N. Les nouveaux anticoagulants oraux : dabigatran, rivaroxaban et apixaban. Leur utilisation actuelle et leur avenir. Med Sci (Paris) 2011 ; 27 : 493-500. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.